Whether ceritinib/ceritinib (Zanda) requires long-term use and treatment course guidance

Ceritinib/Ceritinib (Ceritinib) is an oral ALK span>Tyrosine kinase inhibitors are mainly used to treat patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Since its mechanism of action is to inhibit the ALK signaling pathway of tumor cells, the drug itself cannot completely cure cancer. Therefore, most patients need to take it continuously for a long time to maintain the efficacy and prevent disease progression.

In terms of treatment schedule, ceritinib usually adopts a once-daily oral fixed-dose regimen. The starting dose and specific dose adjustments need to be determined based on the patient's tolerance, liver and kidney function, and comorbid diseases. In the early stages of treatment, doctors will closely observe the patient's side effects and efficacy, and adjust the dosage if necessary to ensure both good efficacy and reduced toxicity.

During long-term medication, patients need regular reexamination, including imaging examinations, routine blood tests, liver and kidney function, and electrocardiogram, to evaluate the efficacy of the drug and monitor potential adverse reactions. If intolerance or serious side effects occur, the doctor may temporarily stop the drug, adjust the dose, or consider combining it with other drugs to prolong the effect.

In addition, patients should maintain a regular life and medication habits during long-term medication, and avoid stopping medication on their own or changing dosages at will. Reasonable management of side effects, regular follow-up and communication with doctors are important links to ensure efficacy, extend progression-free survival and improve quality of life.

Reference materials:https://www.drugs.com/